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Results: Patients received sequential (n=49, 32%) or 
concomitant (n=93, 60%) chemo-radiotherapy. Eleven 
patients received radiotherapy alone.. Competing risks 
analysis found a significantly higher rate of ICDM in the AC 
group compared to SCC (p= 0.0004) but no significant 
difference in incidence of ECDM (p=0.08). LR failure was 
higher in SCC than in AC (p=0.01). There was no significant 
difference between the two histology groups in the 
proportion dying without evidence of disease (p=0.3), see 
Figure. Restricting the analysis to patients with distant 
metastases as first site of failure, there was a significantly 
higher rate of cerebral metastases in AC than in SCC (p= 
0.04), cf. Table 1. 
 
Conclusion: The pattern of first failure in inoperable NSCLC 
differs among patients with AC and SCC with intra-cranial 
distant metastases being more common in AC than in SCC and 
LR relapse being much more frequent in SCC than in AC. 
Experimental treatment strategies should be targeting 
different relapse patters in various histological subtypes. 
Intensification of local therapy for example may yield a 
worse risk/benefit ratio in AC compared to SCC.  
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Purpose or Objective: In addition to its curative use in early 
stage lung cancer, stereotactic ablative radiotherapy (SABR) 
can also potentially be indicated for pulmonary 
oligometastatic disease. This study aims to retrospectively 
analyze treatment outcomes and develop nomograms to 
predict survival. 
 
Material and Methods: From September 2012 to April 2015, 
treatment outcomes and toxicities for 85 cases of SABR in 72 
patients retrospectively reviewed. Prognostic factors were 
analyzed via multivariate analyses using Cox proportional 
hazards regression. Using factors that demonstrated to be 
significant in the Cox regression model, nomograms were 
constructed and validated internally. 
 
Results: After a median follow-up of 15 months, only 1 
patient showed local failure within the radiation field. The 
local failure-free survival (LFFS) rate at 2 years was 98%. The 
1-year and 2-year progression-free survival (PFS) and overall 
survival (OS) rates were 62% and 48%, and 90% and 72%, 
respectively. Multivariate analyses demonstrated that 
controlled primary cancer (p = 0.01), absence of 
extrapulmonary metastatic disease (p = 0.03), and disease-
free interval (DFI) longer than 1 year (p < 0.01) favorably 
affects PFS. Furthermore, the absence of extrapulmonary 
metastatic disease (p < 0.01) and lower performance status 
(p = 0.03) increased OS as well. In terms of internal 
validation, nomograms for PFS and OS revealed C-index of 
0.75 and 0.81, and showed a well-fitted calibration curves, 
respectively. Grade 1 or 2 radiation pneumonitis was found in 
37 cases, and grade 1 chest wall pain was found in 1 case. 
Any grade 3 or higher toxicities were not identified. 
 
 
 
 
Conclusion: SABR demonstrated good local control with 
tolerable adverse effects for pulmonary oligometastases. 
Several factors were predictive for survival. Based on these 
factors, nomograms presented in this study can potentially be 
a useful tool for the prediction of progression-free and 
overall survival rates. 
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Purpose or Objective: To synthesize and compare available 
evidence to compare the Long-Term clinical outcomes of 
proton therapy (PT) with those of carbon ion therapy (CIT) 
for stage I non-small cell lung cancer (NSCLC). 
 
Material and Methods: Clinical trials were searched for in 
Cochrane Library, PubMed, EMBASE,Web of Science and 
Chinese Biomedical Literature Database through Dec 2014. 
Additional articles were identified from searching 
bibliographies of retrieved articles. Two reviewers 
independently selected studies and extract data. Outcomes 
were analyzed by random-effects model meta-analysis and 
reported as odds ratio (OR) with 95% confidence intervals 
(CI). The meta-analysis was conducted with STATA 12.0 
software. 
 
Results: Three retrospective studies were included, the meta 
analysis showed that there were no difference between 
proton therapy and carbon ion radiotherapy for stage I non-
small cell lung cancer in the one year progression-free 
survival(PFS) was OR=1.13(95%CI:0.71,1.79), two years PFS 
was OR=1.25(95%CI:076,2.06),three years PFS was 
OR=1.02(95%CI:0.58,1.79),four years PFS was 
OR=0.73(95%CI:0.36,1.46),five years PFS was 
OR=0.50(95%CI:0.19,1.30), the one year overall survival(OS) 
was OR=1.01(95%CI:0.65,1.55),two years OS was 
OR=0.93(95%CI:0.59,1.46),three years OS was 
OR=0.94(95%CI:0.62,1.41) and four years OS was 
OR=0.65(95%CI:0.36,1.19),but there was difference in five 
years OS was OR=0.37(95%CI:0.16,0.90). 
 
 
 
Conclusion: Our data suggest that the clinical outcomes of 
stage I NSCLC patients treated with PT and CIT may be 
similar. PT may improve 5-year OS compared with CIT. 
However, no firm conclusion concerning the difference in 
clinical outcomes between these two partical therapies can 
be made because of the limitations of retrospective studies; 
more homogeneous prospective data, large multicentric and 
randomized trials are needed to compare the efficacy of PT 
with CIT for stage I NSCLC. 
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Purpose or Objective: Lung and esophageal cancer are 
characterized by aggressiveness and comprehend the 
majority of thorax malignancies. In both pathologies, the 
possibility to stratify patients (pts), early during radiotherapy 
(RT) or chemoradiotherapy (CRT) with interim 18F-FDG-
PET/CT (FDGint) is extremely appealing to optimize 
treatments. CRT-responding pts could benefit from further 
preoperative treatment, while non responding pts should 
discontinue CRT, to avoid toxicity, and not to delay surgery. 
Although controversial findings have been reported on the 
early value of FDGint in thorax cancer, some notable results 
support therapeutic decision based on its analysis. Reviews 
specifically addressing FDGint in thorax cancer are lacking. 
The purpose of this study is to evaluate where and whether 
FDGint may offer predictive and prognostic potentials. 
 
Material and Methods: A comprehensive review of the last 
decade literature was made, assembling studies on FDGint in 
pts affected by lung or esophageal malignances. Six different 
searches were completed on PubMed using keywords 
combined by Boolean operators (and, or). Studies inherent to 
FDGint for adaptive RT (aRT) were also included. Restrictions 
were: papers in English; 3D hybrid PET/CT studies; original 
papers only. Cross-references of the studies selected were 
also manually checked to complete the literature pursuit. 
 
Results: 1121 items in lung cancer and 193 in esophageal 
cancer were found. After the steps of process selection, 17 
studies were extracted for lung cancer (5 related to change 
of FDG uptake, 9 correlation with response and prognosis, 3 
aRT) reporting on 488 pts, and 8 studies for esophageal 
cancer (7 correlation with response and prognosis, 1 aRT) 
reporting on 318 pts. The main metabolic parameters 
correlated with outcomes, progression free survival, 
locoregional control, overall survival were the standardized 
uptake value, metabolic tumor volume, total lesion glycolysis 
and their variations. Lung studies did not give special 
emphasis to statistical analysis, while 6/8 esophageal studies 
reported the results of statistical ROC analysis (Figure). 
Among the 17 lung studies, 14 advocated the predictivity of 
FDGint, 3 showed the improvements by aRT. Among the 8 
esophageal studies, 4 sustained predictivity, 3 did not find 
any correlation, 1 showed the feasibility of aRT. 
 
 
 
Conclusion: Despite heterogeneity, the studies comprised in 
this review denoted FDGint as promising and challenging 
tracer for early assessment of outcomes during CRT. In lung 
cancer papers, all the authors sustain the predictivity of 
response and prognosis of FDGint. In esophageal cancer 
instead, its predictive and prognostic value cannot be 
